Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness ...
Mar 6, 2012
0
0
In patients with invasive breast cancer treated in a general community health care setting, tamoxifen therapy was associated with reduced risTamoxifen, AI therapies linked to reduced risk for contralateral breast cancer in ...
Oct 6, 2016
0
0
A Rhode Island Hospital radiation oncologist says in a new editorial that research exploring the impact of radiotherapy in older women with low risk of breast cancer recurrence has little effect on actual clinical decisions. ...
Aug 21, 2012
0
1
There is clear evidence that extended adjuvant tamoxifen therapy for 10 years reduces local recurrence and improves breast cancer-free survival in women with oestrogen receptor-positive breast cancer. An analysis of large ...
Jul 5, 2018
0
2
Clinical recommendations discouraging the use of CYP2D6 gene testing to guide tamoxifen therapy in breast cancer patients are based on studies with flawed methodology and should be reconsidered, according to the results of ...
Dec 9, 2014
0
0
A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit ...
May 2, 2013
0
0
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan ...
Apr 9, 2013
0
1
Researchers at Karolinska Institutet have developed a method for assessing the effect of tamoxifen, a common drug to prevent the relapse of breast cancer. The key lies in monitoring changes in the proportion of dense tissue, ...
Apr 22, 2013
0
0
